The chEMBL group, located at the EMBL-EBI outstation in Hinxton, United Kingdom, builds databases of drug discovery related data, covering target discovery, lead discovery and optimisation, and then tracks compounds through clinical development. From these databases, 'rules' for drug discover are researched - for example what are the targets most likely to deliver a quality drug, what side-effects are likely for a particular compound, and what type of drug is best suited for a particular target (small molecule, biotherapeutic RNAi, etc).

chEMBL Group.

chEMBL Blog

Selected publications

Can we rationally design promiscuous drugs? A.L. Hopkins, J.S. Mason and J.P. Overington, (2006) Curr. Opin. Struct. Biol., 16, pp. 127-136.

How many drug targets are there? J.P. Overington, B. Al-Lazikani, and A.L. Hopkins (2006) Nat. Rev. Drug Disc., 5, 993-996.

Genomic-scale Prioritisation of Drug Targets: Agüero, F, Al-Lazikani, B, Aslett, M, Berriman, M, Buckner, FS, Campbell, RK, Carmona, S, Carruthers, IM, Chan, AWE, Chen, F, Crowther, GJ, Hertz-Fowler, C, Hopkins, AL, McAllister, G, Nwaka, S, Overington, JP, Pain, A, Paolini, GV, Pieper, U, Ralph, SA, Riechers, A, Roos, DS, Sali, A, Shanmugam, D, Suzuki, T, Van Voorhis, WC, Verlinde, CL. (2008) Nat. Rev. Drug. Discov., 7, pp. 900-907.